PRC
ONCE

Pearl River Capital’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Pearl River Capital’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-800
Closed -$31K – 973
2018
Q4 		$31K Buy
+800
New +$34.7K 0.14% 192

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Pearl River Capital's ONCE Position: Q1 2019 in Review

Pearl River Capital sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 800 shares — an estimated $31K sold.

Pearl River Capital first reported a position in ONCE in Q4 2018 and held it in 1 quarter. The position peaked at $31K in Q4 2018. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

  • Pearl River Capital reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 800 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $31K.
  • Pearl River Capital first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Spark Therapeutics, Inc. Common Stock position peaked at $31K in Q4 2018.
  • 199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.